Scientists test novel HIV vaccine in first human safety trial
NCT ID NCT05182125
Summary
This early-stage study tested the safety and immune response of a new HIV vaccine in 34 healthy, HIV-negative adults. The vaccine used a chimpanzee adenovirus to deliver HIV proteins, followed by a protein booster shot. The main goal was to see if the shots were safe and if they triggered an immune response against HIV.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Aurum Institute Klerksdorp CRS
Klerksdorp, South Africa
-
CAPRISA eThekwini CRS
Durban, South Africa
-
Emavundleni CRS
Cape Town, South Africa
-
Isipingo CRS
Isipingo, South Africa
-
Setshaba Research Centre CRS
Soshanguve, South Africa
-
Soweto HVTN CRS
Johannesburg, South Africa
Conditions
Explore the condition pages connected to this study.